对抗肠道病毒感染以预防1型糖尿病。
Fighting Enteroviral Infections to Prevent Type 1 Diabetes.
作者信息
Nekoua Magloire Pandoua, Mercier Ambroise, Alhazmi Abdulaziz, Sane Famara, Alidjinou Enagnon Kazali, Hober Didier
机构信息
Laboratoire de Virologie ULR3610, Université de Lille, CHU Lille, 59000 Lille, France.
Microbiology and Parasitology Department, College of Medicine, Jazan University, Jazan 82911, Saudi Arabia.
出版信息
Microorganisms. 2022 Apr 1;10(4):768. doi: 10.3390/microorganisms10040768.
Enteroviruses (EVs), especially coxsackieviruses B (CVB), are believed to trigger or accelerate islet autoimmunity in genetically susceptible individuals that results in type 1 diabetes (T1D). Therefore, strategies are needed to fight against EV infections. There are no approved antiviral drugs currently available, but various antiviral drugs targeting viral or host cell proteins and vaccines have recently shown potential to combat CVB infections and may be used as new therapeutic strategies to prevent or reduce the risk of T1D and/or preserve β-cell function among patients with islet autoantibodies or T1D.
肠道病毒（EVs），尤其是B组柯萨奇病毒（CVB），被认为会在遗传易感个体中引发或加速胰岛自身免疫，进而导致1型糖尿病（T1D）。因此，需要采取策略来对抗EV感染。目前尚无获批的抗病毒药物，但最近各种针对病毒或宿主细胞蛋白的抗病毒药物及疫苗已显示出对抗CVB感染的潜力，可作为新的治疗策略用于预防或降低T1D风险和/或维持胰岛自身抗体阳性患者或T1D患者的β细胞功能。
Zotero 插件